Other languages NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Market Closed - Nasdaq Other stock markets 21:00:00 26/04/2024 BST			5-day change	1st Jan Change
12.64 ^USD	+3.31%		+4.51%	-15.37%

04-24	NovoCure Limited Announces Results of the Metis Phase 3 Clinical Trial in Brain Metastases from Non-Small Cell Lung Cancer	CI
04-10	Piper Sandler Raises NovoCure's Price Target to $28 From $25, Maintains Overweight Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

NovoCure Limited Announces Results of the Metis Phase 3 Clinical Trial in Brain Metastases from Non-Small Cell Lung Cancer	04-24
NovoCure Says New Data Show TTFields' Potential Therapeutic Effects in Pancreatic Cancer	04-05
Klinische Phase-3-Studie METIS erreicht primären Endpunkt und zeigt eine statistisch signifikante Verlängerung der Zeit bis zur intrakraniellen Progression bei Patient:innen mit Hirnmetastasen von nicht-kleinzelligem Lungenkrebs	03-28
L’essai clinique de phase 3 METIS a atteint son critère principal, démontrant un allongement statistiquement significatif du délai médian jusqu’à la progression intracrânienne chez les patients porteurs de métastases cérébrales consécutives...	03-28
Aktien New York Schluss: Anleger greifen nach Rücksetzer wieder zu	03-27
Zai Lab, Novocure Say TTFields Therapy Delays Intracranial Progression in Non-Small Cell Lung Cancer Brain Metastases Patients	03-27
Sector Update: Health Care Stocks Edge Higher Pre-Bell Wednesday	03-27
Wall Street Set to Open Higher Wednesday as Investors Eye End-of-Week Economic, Inflation Data	03-27
Sector Update: Health Care	03-27
NovoCure Says Trial of Therapy for Brain Metastases From Lung Cancer Met Primary Endpoint; Shares Jump Pre-Bell	03-27
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Ahead of Fed Board Governor Waller's Speech	03-27
Novocure's lung cancer therapy succeeds in late-stage trial	03-27
Novocure Q4 Net Loss Widens, Revenue Rises	02-22
NovoCure Limited Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-22
Sector Update: Health Care Stocks Softer Late Thursday Afternoon	01-18
Top Midday Gainers	01-18
Sector Update: Health Care Stocks Weaker Thursday Afternoon	01-18
NovoCure Says US FDA Accepts Its Premarket Approval Application for Tumor Treating Fields in Lung Cancer; Shares Rise	01-18
Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer	01-18
NovoCure Limited Announces Last Patient Enrolled in Phase 3 Trident Trial in Newly Diagnosed Glioblastoma	01-09

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Other languages

Filters